Title
Alzheimer's Clinical Trials Consortium (ACTC) (U24)
Agencies
National Institutes of Health (NIH)
Description
This Funding Opportunity Announcement (FOA) invites applications to establish an Alzheimer's disease Clinical Trials Consortium (ACTC) that will run trials focused on interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age related dementias. The ACTC will include multiple clinical trials sites and trial coordination and management infrastructure. A separate FOA will solicit applications for clinical trials to be managed and supported by the ACTC.
The ACTC will conduct clinical trials (Phase I to III) of promising pharmacological and non- pharmacological interventions for cognitive and neuropsychiatric symptoms in individuals with AD and other age related dementias across the spectrum from pre-symptomatic to more severe stages of disease. The ACTC will provide a state-of-the-art clinical trial infrastructure to facilitate rapid development and implementation of protocols. The ACTC will also provide leadership to the field in innovative trial design methods, outcomes and analyses as well as recruitment strategies, particularly in diverse populations.
More Information
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-005.html
Submission Limits
Only one application per institution is allowed, as defined in Section III. 3. Additional Information on Eligibility. See Section III. 3. Additional Information on Eligibility.
Deadlines
Internal Notice of Intent |
Aug 18, 2016 |
Notification of Internal Competition |
Aug 19, 2016 |
Internal Pre-proposal |
Sep 2, 2016 |
Results of Internal Competition |
Sep 16, 2016 |
Agency Notice of Intent/Pre-proposal |
Jan 2, 2017 |
Agency Proposal |
Feb 2, 2017
|
|